Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chadi Hage Chehade

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
CA: a Cancer Journal for Clinicians|January 10, 2025
A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitorsChadi Hage Chehade, Georges Gebrael, Nicolas Sayegh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2025
Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate CancerChadi Hage Chehade, Ryon P Graf, Zeynep Irem Ozay, et al.
Diagnostics (Basel, Switzerland)|September 14, 2024
Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate CarcinomaEmre Dal, Ayana Srivastava, Beverly Chigarira, et al.
Clinical Genitourinary Cancer|December 25, 2024
Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial CarcinomaNicolas Sayegh, Yeonjung Jo, Georges Gebrael, et al.
Therapeutic Advances in Urology|November 11, 2024
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolixPatrick Campbell, Georges Gebrael, Arshit Narang, et al.
Prostate Cancer and Prostatic Diseases|January 30, 2025
Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapyGeorges Gebrael, Nicolas Sayegh, Chadi Hage Chehade, et al.
JAMA Network Open|July 18, 2024
Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial CancersChadi Hage Chehade, Yeonjung Jo, Georges Gebrael, et al.
JAMA Network Open|May 2, 2024
Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the USVinay Mathew Thomas, Yeonjung Jo, Nishita Tripathi, et al.
Kidney Cancer (Clifton, Va.)|September 12, 2024
Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based CombinationsArshit Narang, Georges Gebrael, Yeonjung Jo, et al.
Journal of Kidney Cancer and VHL|April 30, 2025
First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell CarcinomaMicah Ostrowski, Yeonjung Jo, Georges Gebrael, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
CA: a Cancer Journal for Clinicians|January 10, 2025
A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitorsChadi Hage Chehade, Georges Gebrael, Nicolas Sayegh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2025
Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate CancerChadi Hage Chehade, Ryon P Graf, Zeynep Irem Ozay, et al.
Diagnostics (Basel, Switzerland)|September 14, 2024
Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate CarcinomaEmre Dal, Ayana Srivastava, Beverly Chigarira, et al.
Clinical Genitourinary Cancer|December 25, 2024
Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial CarcinomaNicolas Sayegh, Yeonjung Jo, Georges Gebrael, et al.
Therapeutic Advances in Urology|November 11, 2024
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolixPatrick Campbell, Georges Gebrael, Arshit Narang, et al.
Prostate Cancer and Prostatic Diseases|January 30, 2025
Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapyGeorges Gebrael, Nicolas Sayegh, Chadi Hage Chehade, et al.
JAMA Network Open|July 18, 2024
Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial CancersChadi Hage Chehade, Yeonjung Jo, Georges Gebrael, et al.
JAMA Network Open|May 2, 2024
Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the USVinay Mathew Thomas, Yeonjung Jo, Nishita Tripathi, et al.
Kidney Cancer (Clifton, Va.)|September 12, 2024
Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based CombinationsArshit Narang, Georges Gebrael, Yeonjung Jo, et al.
Journal of Kidney Cancer and VHL|April 30, 2025
First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell CarcinomaMicah Ostrowski, Yeonjung Jo, Georges Gebrael, et al.
Pageof 3